Clinical Trials Logo

Recurrent Glioma clinical trials

View clinical trials related to Recurrent Glioma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06397560 Not yet recruiting - Glioma Clinical Trials

PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial

POPCORN
Start date: June 2024
Phase: N/A
Study type: Interventional

The purpose of this research study is to see if a specific type of radiation therapy, called "proton pulsed reduced dose rate" or "PRDR radiotherapy" has any benefits at dose levels and number of fractions thought to be acceptable in earlier research studies. The researchers want to find out what effects (good and bad) PRDR has on people with cancer in the brain called a "recurrent high-grade glioma" meaning that it grows fast, can spread quickly, and it has come back or gotten worse after being treated previously.

NCT ID: NCT05676489 Not yet recruiting - Healthy Volunteers Clinical Trials

MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors

Start date: December 30, 2024
Phase: Early Phase 1
Study type: Interventional

This first-in-human study will establish the human safety and radiation dosimetry of the system A amino acid transport substrate, (R)-3-[F-18]fluoro-2-methyl-2-(methylamino)propanoic acid ([F-18]MeFAMP), for positron emission tomography (PET) imaging of primary and metastatic brain tumors. This study will include 3 cohorts: healthy volunteers for whole body dosimetry estimates (n=6-8, Dosimetry Cohort), patients undergoing evaluation for recurrent high grade glioma after radiation therapy (n=10, high grade glioma (HGG) Cohort), and patients with brain metastases from extra-cranial solid tumors before and after radiation therapy (n=10, Metastasis Cohort). Exploratory assessment of the diagnostic accuracy of MeFAMP for distinguishing recurrent/progressive brain tumors from radiation-related treatment effects will also be performed for subsequent trial design. The study will complete accrual and safety assessment in the Dosimetry Cohort before recruiting for the HGG and Metastasis Cohorts.

NCT ID: NCT04562077 Not yet recruiting - Glioma, Malignant Clinical Trials

Role of Surgery in Treatment of Recurrent Brian Glioma:Prognostic Factors and Outcome

Start date: October 2020
Phase:
Study type: Observational

role of surgery in treatment of recurrent brain glioma prognostic factors and outcome measures Role of surgery : In patients with Grade I gliomas, such as pilocytic astrocytomas, resection is potentially curative. For more diffuse invasive gliomas (Grade II or higher), initial management typically includes maximal safe resection when possible. Increasing evidence supports an association between extent of resection and prolonged progression-free and overall survival for patients with diffuse gliomas of all types and grades Many studies reported that more that 90%of patients with glioma showed recurrence at the orginal tumor location. Review the outcomes of re-operation in treatment of recurrent brain gliomas To determine the prognostic factors which can predict which patient would benefit from multiple surgery . Trail to Improve the outcome of these patients and decrease rate of complications